EA201290952A1 - Химические соединения - Google Patents
Химические соединенияInfo
- Publication number
- EA201290952A1 EA201290952A1 EA201290952A EA201290952A EA201290952A1 EA 201290952 A1 EA201290952 A1 EA 201290952A1 EA 201290952 A EA201290952 A EA 201290952A EA 201290952 A EA201290952 A EA 201290952A EA 201290952 A1 EA201290952 A1 EA 201290952A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- relates
- disease
- compound
- cancer
- activity
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Изобретение относится к замещенным производным индолина. В частности, изобретение относится к соединениям согласно формуле (I)в которых R, Rи Rопределены в описании. Соединения по изобретению являются ингибиторами PERK и могут быть использованы в лечении рака, глазных заболеваний и заболеваний, связанных с путями ответов на активированные нескрученные белки, таких как болезнь Альцгеймера, инсульт, диабет типа 1, болезнь Паркинсона, болезнь Гентингтона, боковой амиотрофический склероз, инфаркт миокарда, сердечно-сосудистое заболевание, атеросклероз и аритмии, более конкретно, рак молочной железы, толстой кишки, поджелудочной железы и легкого. Соответственно, изобретение также относится к фармацевтическим композициям, включающим соединение по изобретению. Изобретение также относится к способам ингибирования активности PERK и лечения нарушений, связанных с этой активностью, с использованием соединения по изобретению или фармацевтической композиции, включающей соединение по изобретению.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31747610P | 2010-03-25 | 2010-03-25 | |
US35286310P | 2010-06-09 | 2010-06-09 | |
US38148010P | 2010-09-10 | 2010-09-10 | |
US38815110P | 2010-09-30 | 2010-09-30 | |
US41906810P | 2010-12-02 | 2010-12-02 | |
PCT/US2011/029511 WO2011119663A1 (en) | 2010-03-25 | 2011-03-23 | Chemical compounds |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201290952A1 true EA201290952A1 (ru) | 2013-04-30 |
EA022325B1 EA022325B1 (ru) | 2015-12-30 |
Family
ID=46160738
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201290952A EA022325B1 (ru) | 2010-03-25 | 2011-03-23 | Производные индолина как ингибиторы perk |
Country Status (15)
Country | Link |
---|---|
US (1) | US20120077828A1 (ru) |
EP (1) | EP2549868B1 (ru) |
JP (1) | JP5876031B2 (ru) |
KR (1) | KR101676077B1 (ru) |
CN (1) | CN102917588B (ru) |
AR (1) | AR080792A1 (ru) |
AU (1) | AU2011232516B2 (ru) |
EA (1) | EA022325B1 (ru) |
ES (1) | ES2530955T3 (ru) |
IL (1) | IL222120A (ru) |
MX (1) | MX2012011045A (ru) |
SG (1) | SG183954A1 (ru) |
TW (1) | TW201202241A (ru) |
UY (1) | UY33288A (ru) |
WO (1) | WO2011119663A1 (ru) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
US20140227289A1 (en) * | 2011-05-13 | 2014-08-14 | Stephen Michael Cohen | Compounds and methods for treating insulin resistance syndrome |
CN106243113B (zh) | 2011-07-19 | 2018-12-18 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
EP2548877A1 (en) | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
US9550750B2 (en) | 2012-10-05 | 2017-01-24 | Merck Sharp & Dohme Corp. | Indoline compounds as aldosterone synthase inhibitors |
MX2015009270A (es) | 2013-01-18 | 2015-10-30 | Hoffmann La Roche | Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk). |
CA2901267C (en) * | 2013-04-04 | 2021-01-19 | Janssen Pharmaceutica Nv | Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors |
TWI482757B (zh) * | 2013-10-07 | 2015-05-01 | Luminescence Technology Corp | Vegf-2/3受體及蛋白質酪胺酸激酶抑制劑及其醫藥用途 |
WO2015056180A1 (en) * | 2013-10-15 | 2015-04-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Indoline derivatives as inhibitors of perk |
EP3076974A1 (en) | 2013-12-05 | 2016-10-12 | Acerta Pharma B.V. | Therapeutic combination of a pi3k inhibitor and a btk inhibitor |
US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
EP3116877A1 (en) * | 2014-03-11 | 2017-01-18 | Glaxosmithkline Intellectual Property (No. 2) Limited | Chemical compounds acting as perk inhibitors |
US9937171B2 (en) | 2014-04-11 | 2018-04-10 | Acerta Pharma B.V. | Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase |
WO2015193740A2 (en) | 2014-06-17 | 2015-12-23 | Acerta Pharma B.V. | Therapeutic combinations of a btk inhibitor, a pi3k inhibitor and/or a jak-2 inhibitor |
LT3179991T (lt) | 2014-08-11 | 2021-11-10 | Acerta Pharma B.V. | Terapiniai btk inhibitoriaus ir bcl-2 inhibitoriaus deriniai |
EA034931B1 (ru) | 2014-10-24 | 2020-04-08 | Бристол-Майерс Сквибб Компани | Индолкарбоксамидные соединения |
CA2967125C (en) | 2014-11-14 | 2022-10-25 | Nerviano Medical Sciences S.R.L. | 6-amino-7-bicyclo-7-deaza-purine derivatives as protein kinase inhibitors |
WO2016126026A2 (ko) * | 2015-02-04 | 2016-08-11 | 서울대학교병원 | 당뇨병 치료 조성물 및 이의 용도 |
MA50817B1 (fr) | 2015-07-02 | 2021-10-29 | Acerta Pharma Bv | Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide |
TW201722957A (zh) * | 2015-09-15 | 2017-07-01 | 葛蘭素史克智慧財產(第二)有限公司 | 化學化合物 |
WO2017046739A1 (en) * | 2015-09-15 | 2017-03-23 | Glaxosmithkline Intellectual Property (No.2) Limited | Imidazolidinone derivatives as inhibitors of perk |
SI3440076T1 (sl) * | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
WO2017189837A1 (en) * | 2016-04-29 | 2017-11-02 | The Trustees Of The University Of Pennsylvania | Protein kinase rna-like endoplasmic reticulum kinase (perk) inhibitors for prevention and/or treatment of lung injury and/or inflammation |
EP3472133B1 (en) | 2016-06-13 | 2023-10-11 | Ramot at Tel-Aviv University Ltd. | Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins |
US10561660B2 (en) | 2016-06-21 | 2020-02-18 | Nerviano Medical Sciences S.R.L. | N-(substituted-phenyl)-sulfonamide derivatives as kinase inhibitors |
WO2018015879A1 (en) * | 2016-07-20 | 2018-01-25 | Glaxosmithkline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
US11759437B2 (en) * | 2016-09-22 | 2023-09-19 | The University Of Hong Kong | Preventive and therapeutic approach for aberrant cell differentiation and ISR-associated diseases |
US20190388426A1 (en) | 2017-01-30 | 2019-12-26 | Université de Liège | Perk and ire-1a inhibitors against neurodevelopmental disorders |
CN106974910B (zh) * | 2017-03-02 | 2019-11-12 | 深圳大学 | 含索拉非尼和gsk2656157的药物组合物及用途 |
CN106963769B (zh) * | 2017-03-03 | 2019-10-25 | 深圳大学 | 含pi3k抑制剂和perk抑制剂的药物组合物及其应用 |
WO2018164113A1 (ja) | 2017-03-06 | 2018-09-13 | 学校法人 慶應義塾 | マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤 |
DK3448859T3 (da) * | 2017-03-20 | 2019-09-23 | Forma Therapeutics Inc | Pyrrolopyrrolsammensætninger som pyruvatkinase- (pkr) aktivatorer |
WO2019021208A1 (en) * | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
CN108003163B (zh) * | 2017-11-30 | 2020-11-24 | 武汉九州钰民医药科技有限公司 | 用作激酶抑制剂的吡唑并嘧啶类化合物及其应用 |
CN111100130B (zh) * | 2018-10-29 | 2022-07-15 | 四川大学 | 4-氨基吡咯并嘧啶衍生物及其制备方法和用途 |
CN111213632B (zh) * | 2019-11-19 | 2022-03-01 | 长春中医药大学 | 动物药环氧树脂标本制作方法 |
CA3186041A1 (en) | 2020-06-08 | 2021-12-16 | Halia Therapeutics, Inc. | Inhibitors of nek7 kinase |
US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
WO2022212326A1 (en) | 2021-03-29 | 2022-10-06 | Halia Therapeutics, Inc. | Nek7 inhibitors |
AU2022255486A1 (en) | 2021-04-05 | 2023-10-19 | Halia Therapeutics, Inc. | Nek7 inhibitors |
WO2023034236A1 (en) * | 2021-08-31 | 2023-03-09 | Wisconsin Alumni Research Foundation | Deuterated inhibitors of rip kinases |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060074102A1 (en) * | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
PL1761528T3 (pl) * | 2004-06-11 | 2008-05-30 | Japan Tobacco Inc | Pochodne 5-amino-2,4,7-triokso-3,4,7,8-tetrahydro-2H-pirydo[2,3-D]pirymidyny i związki pokrewne do leczenia raka |
US20080255184A1 (en) * | 2005-11-04 | 2008-10-16 | Smithkline Beecham Corporation | Thienopyridine B-Raf Kinase Inhibitors |
EP2368566A1 (en) * | 2006-07-13 | 2011-09-28 | ZymoGenetics, Inc. | Interleukin 21 and tyrosine kinase inhibitor combination therapy |
WO2009151621A1 (en) * | 2008-06-13 | 2009-12-17 | Arena Pharmaceuticals, Inc. | Substituted (1, 2, 4-0xadiaz0l-3-yl) indolin-1-yl carboxylic acid derivatives useful as s1p1 agonists |
JP5746032B2 (ja) * | 2008-09-19 | 2015-07-08 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 3,4−ジヒドロ−2H−ピロロ[1,2−a]ピラジン−1−オン誘導体 |
-
2011
- 2011-03-22 UY UY0001033288A patent/UY33288A/es not_active Application Discontinuation
- 2011-03-23 ES ES11760102T patent/ES2530955T3/es active Active
- 2011-03-23 TW TW100109800A patent/TW201202241A/zh unknown
- 2011-03-23 MX MX2012011045A patent/MX2012011045A/es active IP Right Grant
- 2011-03-23 SG SG2012066379A patent/SG183954A1/en unknown
- 2011-03-23 JP JP2013501421A patent/JP5876031B2/ja not_active Expired - Fee Related
- 2011-03-23 AU AU2011232516A patent/AU2011232516B2/en not_active Ceased
- 2011-03-23 WO PCT/US2011/029511 patent/WO2011119663A1/en active Application Filing
- 2011-03-23 EA EA201290952A patent/EA022325B1/ru not_active IP Right Cessation
- 2011-03-23 EP EP11760102.1A patent/EP2549868B1/en active Active
- 2011-03-23 AR ARP110100955A patent/AR080792A1/es not_active Application Discontinuation
- 2011-03-23 CN CN201180025962.7A patent/CN102917588B/zh not_active Expired - Fee Related
- 2011-03-23 KR KR1020127027705A patent/KR101676077B1/ko active IP Right Grant
- 2011-03-23 US US13/069,569 patent/US20120077828A1/en not_active Abandoned
-
2012
- 2012-09-24 IL IL222120A patent/IL222120A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR101676077B1 (ko) | 2016-11-14 |
WO2011119663A8 (en) | 2012-10-26 |
EP2549868B1 (en) | 2015-01-07 |
US20120077828A1 (en) | 2012-03-29 |
AU2011232516B2 (en) | 2014-08-07 |
KR20130018272A (ko) | 2013-02-20 |
AU2011232516A8 (en) | 2012-12-13 |
AR080792A1 (es) | 2012-05-09 |
JP5876031B2 (ja) | 2016-03-02 |
TW201202241A (en) | 2012-01-16 |
JP2013534902A (ja) | 2013-09-09 |
ES2530955T3 (es) | 2015-03-09 |
SG183954A1 (en) | 2012-10-30 |
AU2011232516A1 (en) | 2012-10-04 |
CN102917588A (zh) | 2013-02-06 |
UY33288A (es) | 2011-10-31 |
WO2011119663A1 (en) | 2011-09-29 |
IL222120A (en) | 2015-09-24 |
EA022325B1 (ru) | 2015-12-30 |
MX2012011045A (es) | 2012-11-16 |
EP2549868A4 (en) | 2013-08-07 |
CN102917588B (zh) | 2014-10-08 |
EP2549868A1 (en) | 2013-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201290952A1 (ru) | Химические соединения | |
WO2015056180A8 (en) | Indoline derivatives as inhibitors of perk | |
BR112015012454A2 (pt) | compostos úteis como inibidores de atr cinase | |
BR112012024380A2 (pt) | compostos químicos | |
BR112012020922A2 (pt) | compostos de pirrolopirimidina como inibidores de cdk4/6. | |
BR112012033402A2 (pt) | moduladores de canais de íons conforme os compostos heterocíclicos fundidos | |
BR112014007163A2 (pt) | composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida | |
PH12015501116A1 (en) | New indanyloxydihydrobenzofuranylacetic acids | |
PH12014502141A1 (en) | New indanyloxydihydrobenzofuranylacetic acid derivatives and their use as gpr40 receptor agonists | |
UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
EA201001647A1 (ru) | Производные бензофурана, бензотиофена, бензотиазола в качестве fxr модуляторов | |
EA201100299A1 (ru) | Органические соединения | |
TR201903492T4 (tr) | Apomorfin ve organik asitler içeren bileşimler ve bunların kullanım alanları. | |
EA201300550A1 (ru) | Фармацевтическая композиция, способы лечения и их применение | |
JO2870B1 (en) | Amino Tetra Hydro Pirans as Inhibitors of Peptide Dipeptide IV for the Treatment or Prevention of Diabetes | |
EA201071045A1 (ru) | Соединения оксадиазоантрацена для лечения диабета | |
MX356584B (es) | Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica. | |
EA201491335A1 (ru) | Бигуанидные композиции и способы лечения метаболических расстройств | |
EA201070477A1 (ru) | Транс-кломифен для лечения метаболического синдрома | |
WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
PH12014502239A1 (en) | Use of ccr3-inhibitors | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
EP2257161A4 (en) | AHCY HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPER-HOMOCYSEINEMIA | |
EA201200046A1 (ru) | Новые соединения, фармацевтическая композиция и связанные с ними способы | |
PH12015500860A1 (en) | 2-phenyl -5- heterocyclyl -tetrahydro-2h- pyran-3-amine compounds for use in the treatment of diabetes and its associated disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |